Cohen, OC;
              
      
            
                Counsell, N;
              
      
            
                Rabin, N;
              
      
            
                Popat, R;
              
      
            
                Owen, RG;
              
      
            
                Popova, B;
              
      
            
                Schofield, O;
              
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
          
      
            
            
            ... Yong, KL; + view all
            
          
      
        
        
        
    
  
(2019)
  Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
[Letter].
British Journal of Haematology
, 185
       (5)
    
     pp. 948-951.
    
         10.1111/bjh.15649.
  
  
       
    
  
| Preview | Text Clifton-Hadley_Cohen et al Letter.oc 28Aug2018.pdf - Accepted Version Download (485kB) | Preview | 
Archive Staff Only
|  | View Item | 
 
                      
